Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Bayer AG buy gerihouse

Start price
€107.03
26.01.17 / 50%
Target price
€125.00
07.06.17
Performance (%)
12.55%
End price
€117.76
07.06.17
Summary
This prediction ended on 07.06.17 with a price of €117.76. The BUY prediction by gerihouse finished with a performance of 12.55%. gerihouse has 50% into this prediction

Bayer is a multinational pharmaceutical and life sciences company headquartered in Germany. The company was founded in 1863 and has since grown to become a global leader in the fields of pharmaceuticals, agriculture, and consumer health. Bayer is listed on the Frankfurt Stock Exchange and also trades over-the-counter in the United States under the ticker symbol BAYZF. The company's products include prescription drugs, over-the-counter medicines, and agrochemicals, and it operates in more than 90 countries around the world.

Performance without dividends (%)
Name 1w 1m 1y 3y
Bayer AG -2.266% -2.266% -57.017% -52.311%
iShares Core DAX® -0.870% -1.700% 10.560% 13.129%
iShares Nasdaq 100 -5.561% -3.604% 34.335% 39.856%
iShares Nikkei 225® -6.138% -7.732% 16.215% 0.044%
iShares S&P 500 -3.141% -2.011% 24.534% 39.859%

According to gerihouse what are the pros and cons of Bayer AG for the foreseeable future?

Pros
Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
Future proof or reliable business model
High dividend yield expected
Innovative
Good rating
Cons

Comments by gerihouse for this prediction

In the thread Bayer AG diskutieren
Prediction Buy
Perf. (%) 12.55%
Target price 125.000
Change
Ends at 07.06.17

Dividenden Aktie


Das US-Analysehaus Bernstein
Research hat Bayer auf "Outperform" mit einem Kursziel von 120 Euro
belassen. Seine Kontakte in der Branche gingen einhellig davon aus,
dass der Pharma- und Pflanzenschutzkonzern nach der geplanten
Übernahme des US-Saatgutherstellers Monsanto erheblich von dessen
starker Position bei Soja-Saatgut profitieren werde, schrieb Analyst
Jeremy Redenius in einer Studie vom Donnerstag. Zudem sehe er nach
der bisherigen 50-prozentigen nun eine 75-prozentige
Erfolgswahrscheinlichkeit für die Übernahme.



Die US-Investmentbank Goldman Sachs
hat das Kursziel für Bayer von 129 auf 120 Euro gesenkt und die
Einstufung auf "Buy" belassen. Im Pharmabereich sei die Auswahl der
richtigen Aktie derzeit der Schlüssel zum Erfolg, schrieb Analyst
Keyur Parekh in einer Branchenstudie vom Dienstag. Roche und Shire
seien mit Blick auf 2017 seine bevorzugten Werte, gefolgt von Novo
Nordisk, Bayer und Glaxo. Die Kursziele macht der Experte fortan an
seinen überarbeiteten Gewinnschätzungen für 2018 fest



Prediction Buy
Perf. (%) 12.55%
Target price 125.000
Change
Ends at 07.06.17

(Stop Loss Kurs erreicht)

Stopped prediction by gerihouse for Bayer AG

buy
Bayer AG

Start price
Target price
Perf. (%)
€49.60
10.01.22
€70.00
10.01.23
3.36%
22.01.22

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€58.86
04.05.20
€55.00
04.11.21
-15.30%
05.11.21

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€55.37
06.04.20
€70.00
18.04.20
6.30%
18.04.20

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€60.00
09.03.20
€80.00
16.03.20
-23.30%
16.03.20

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€63.61
14.08.19
€82.00
09.03.20
-5.68%
09.03.20

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€53.21
14.06.19
€89.00
08.07.19
12.65%
08.07.19

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€76.80
12.10.18
€89.00
21.03.19
-20.20%
21.03.19

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€111.80
26.09.17
€130.00
06.09.18
-28.07%
06.09.18

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€89.85
07.10.16
€98.00
19.12.16
9.10%
19.12.16

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€97.56
08.03.16
€120.00
30.08.16
2.23%
30.08.16

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€123.32
04.11.15
€152.00
08.02.16
-21.77%
08.02.16

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€110.85
07.01.15
€135.00
06.02.15
12.72%
06.02.15

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€85.44
16.05.13
€90.50
05.08.13
5.93%
05.08.13

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies
buy
Bayer AG

Start price
Target price
Perf. (%)
€56.02
01.03.12
€60.00
20.06.12
0.22%
20.06.12

Could be worthwhile Investment >10% per year
Top 10 in its market
Known brand
Small cyclical dependencies